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Abstract: Lung cancer is a leading cause of cancer deaths worldwide. Metabolic alterations 
in tumor cells coupled with systemic indicators of the host response to tumor development 
have the potential to yield blood profiles with clinical utility for diagnosis and monitoring of 
treatment. We report results from two separate studies using gas chromatography time-of-flight 
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mass spectrometry (GC-TOF MS) to profile metabolites in human blood samples that 
significantly differ from non-small cell lung cancer (NSCLC) adenocarcinoma and other 
lung cancer cases. Metabolomic analysis of blood samples from the two studies yielded a 
total of 437 metabolites, of which 148 were identified as known compounds and 289 identified 
as unknown compounds. Differential analysis identified 15 known metabolites in one study 
and 18 in a second study that were statistically different (p-values <0.05). Levels of maltose, 
palmitic acid, glycerol, ethanolamine, glutamic acid, and lactic acid were increased in cancer 
samples while amino acids tryptophan, lysine and histidine decreased. Many of the 
metabolites were found to be significantly different in both studies, suggesting that 
metabolomics appears to be robust enough to find systemic changes from lung cancer, thus 
showing the potential of this type of analysis for lung cancer detection. 
Keywords: metabolomics; lung cancer; mass spectrometry; blood  
 
1. Introduction 
Lung cancer continues to be the leading cause of cancer death for men and women in the United 
States in spite of reduced rates in smoking [1]. Furthermore, there is an increased global burden of lung 
cancer largely due to increased smoking in economically developing countries [2]. Only 16% of cases 
with non-small cell lung cancer (NSCLC) survive longer than 5 years, largely due to late stage diagnosis 
and metastasis of this disease. Early diagnosis significantly improves the 5 year survival rate for lung 
cancer [3]. Currently, there are no FDA-approved diagnostic tests available to detect the presence of 
lung cancer, especially in the high-risk smoking population. Results from the National Lung Screening 
Trial (NLST) showed that CT screening could reduce mortality by 6.7% [4]. However, CT screening is 
not cost-effective, has a high false positive rate and can expose the patient to low amounts of  
radiation [5]. There is also variability in the reading and interpretation of radiographic scans, thereby 
reducing the enthusiasm of CT screening for routine clinical use [6]. Ideally what is needed is a non-invasive 
blood analysis for biomarkers capable of assisting with diagnosis that might also help reduce the high 
false positive rate of CT scan screening [7,8]. 
Metabolomic changes in cancer are well-documented with increased glycolysis and decreased 
oxidative phosphorylation (the “Warburg effect”), as described by Deberardinis et al. [9]. Of particular 
interest are components of the glycolytic pathway, nucleotide, amino acid and fatty acid synthesis and 
how tumor cells are able to scavenge the available cellular and environment material to produce the 
necessary cellular components to support increased growth and proliferation. Metabolomic analysis has 
been used to distinguish between benign prostatic hyperplasia (BPH) and prostate cancer in urine 
samples [10], and invasive ovarian carcinoma tumors compared with borderline tumors in tissues [11], 
thus yielding potential biomarker panels for breast, ovarian and gastric cancers [12–16]. Maeda et al. 
used metabolomics to examine levels of plasma amino acids in the blood of patients with lung  
cancer [17]. Analysis of metabolic pathways has identified glycolytic and signaling pathways differentially 
regulated in pre-diagnostic blood samples from subjects diagnosed with breast cancer [18] and  
AMPK-related alterations in ovarian cancer [19]. Thus, measuring changes in metabolites detectable in 
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blood samples that may represent tumorigenesis has the potential to yield suspicious systemic 
metabolitic changes indicating the presence of lung tumors [20–22]. The purpose of this study is to 
perform metabolomic analysis of blood samples from two separate case-control studies obtained from 
two different sites  to determine if untargeted metabolic profiling by GC-TOF MS can  identify metabolic 
differences in patients with lung cancer when compared with blood samples from those without cancer. 
2. Results and Discussion 
2.1. Differential Analysis Results of Cancer Cases and Controls 
Gas chromatography (GC) time of flight (TOF) mass spectrometry (MS) was used to analyze  
pre-existing blood samples provided by two separate sites in pilot lung cancer case control studies. For 
Study 1, samples were acquired from the Fred Hutchison Cancer Research Center (FHCRC) (Table 1A) 
comparing blood samples from NSCLC adenocarcinomas with controls (all current or former smokers 
frequency matched for age and gender). All patient samples for Study 1 (cases) were collected during a 
clinic visit prior to surgery for resectable early stage lung cancer and the controls were collected from 
clinic subjects without lung cancer. For Study 2, samples were acquired from University of California 
at Davis Medical Center (UCDMC) (Table 1B) and included a variety of lung cancers. For Study 1, 20 
control subjects were compared to 18 cases. Data from two samples were not included in the analysis 
due to low analytical results for these samples. 
Data results were differentially analyzed (see methods for details). In Study 1, based on p-values  
(p < 0.05), 19 metabolites differed significantly by cancer status (15 known metabolites and 4 unknown, 
shown highlighted in grey in Supplemental Table S1, left side). Data for 9 of the top 15 known 
metabolites from Study 1 with mean values, fold changes and p-values are shown in Table 2A. These 
metabolites are maltose, ethanolamine, glycerol, palmitic acid, lactic acid, tryptophan, lysine, histidine 
and glutamic acid. (Supplemental Table S2 show mean values, fold changes and p-values for all known 
and unknown compounds measured in Study 1). 
In Study 2, 82 metabolites differed significantly for cancer versus control samples based on  
p-values (p < 0.05) (18 known metabolites and 64 unknown). Data for all of the metabolites (known and 
unknown) in Study 2 are shown in Supplemental Table S1(middle section) with the 82 metabolites with 
p-value < 0.05 highlighted in grey. Results (mean values, fold change, p-values) of the same 9 metabolitles 
as shown for Study 1 (Table 2A) are listed in Table 2B for comparison. These results show similar 
changes in these metabolites (increase or decrease) in both studies with the exception of glutamic acid, 
which shows an increase in Study 1 and a decrease in Study 2. Supplemental Table S2 show mean values, 
fold changes and p-values for all known and unknown compounds measured in Study 2.  
Metabolites 2015, 5 195 
 
 
Table 1. Summary of patient information for FHCRC and UCDMC samples. SE is standard error of the mean. 
 Type and Stage Female Male Total Smoking History 
(A) Study 1 (38 Samples) 
Lung cancer 
NSCLC adenocarcinoma 
stage unknown 
8 10 18 
Current or former 
smokers 
Control  12 8 20 
Current or former 
smokers 
Average age (cancer)  
62 (SE 2.38)  
(range 53–72) 
67 (SE 3.66)  
(range 50–85) 
  
Average age (control)  
64 (SE 2.71)  
(range 49–80) 
66 (SE 2.65)  
(range 58–82) 
  
(B) Study 2 (22 Samples) 
Lung cancer 
 7 4 11  
NSCLC Stage I-IIB 1  1 1 former smoker 
NSCLC Stage IIIA-IV 2 2 4 
1 never smoker 
1 former smoker 
SCLC 3  3 
1 unknown,  
1 former smoker 
1 current smoker 
Mesothelioma  1 1 1 former smoker 
Secondary 2nd metastasis 
to lung 
 1 1 1 former smoker 
other 1  1 1 former smoker 
Control  6 5 11 unknown 
Average age (cancer)  
67 (SE 4.2) 
(range 47–76) 
67 (SE 2.66) 
(range 61–73) 
11  
Average age (control)  
54 (SE 2.64) 
(range 44–61) 
69 (SE 3.79) 
(range 61–83) 
11  
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Table 2. (A) Means and fold change for nine known metabolites from Study 1 that differ 
significantly (raw p-value < 0.05) between cancer patients and disease free controls;  
(B) means and fold change for nine known metabolites from Study 2. 
Metabolite Mean Cancer Mean Control Fold (Cancer/Control) Raw p-Value 
(A) Study 1 (FHCRC) 
Maltose 1298 780 1.664 0.013 
Ethanolamine 156,214 123,699 1.263 0.016 
Glycerol 66,463 49,062 1.355 0.023 
Palmitic acid 53,763 41,293 1.302 0.047 
Lactic acid 380,753 301,909 1.261 0.055 
Tryptophan 121,513 143,383 0.847 0.005 
Lysine 159,156 179,325 0.888 0.042 
Histidine 30,526 37,025 0.824 0.036 
Glutamicacid 39,179 27,794 1.410 0.026 
(B) Study 2 (UC Davis) 
Maltose 1061 989 1.074 0.819 
Ethanolamine 150,655 127,546 1.181 0.006 
Glycerol 67,557 47,052 1.436 0.315 
Palmitic acid 50,740 43,659 1.162 0.797 
Lactic acid 381,850 296,663 1.287 0.108 
Tryptophan 126,621 139,426 0.908 0.391 
Lysine 167,528 172,015 0.974 0.636 
Histidine 31,053 36,840 0.843 0.047 
Glutamicacid 31,486 34,887 0.903 0.914 
Box-plots comparing the mean intensities of 9 of the top candidate metabolites for all samples listed 
in Table 2A,B from Study 1 and Study 2 are shown in Figure 1. Also shown in Figure 1 are additional 
box plots to show a comparison between results from males (blue) and females (red) for the two studies. 
These plots show the same trends (increased or decreased) as all samples with the exception of glutamic 
acid, which shows the same trend for females, but not for males. This striking similarity between the 
studies is notable, especially since both studies were quite small and involved differences in the matrix 
(plasma and serum), dealt with different types of lung cancers and originated from different clinics. 
Overall, we concluded that it is possible to compare the two studies and still find evidence of an increase 
in glycolysis and lipid biosynthesis in blood samples, along with a general decrease in aromatic amino acids. 
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Figure 1. Box-whisker plots of top metabolite candidates in Study 1 and Study 2 with 
additional plots of the same metabolites from each study separated by gender (males and 
females). Box-whisker plots of gender adjusted intensities of top known metabolite 
candidates from Study 1 (S1) compared with the same compounds in Study 2 (S2) for cancer 
cases (C) and normal/control (N) showing similarity in the changes in both studies are shown 
for nine of the top metabolites: maltose, ethanolamine, glycerol, palmitic acid, lactic acid, 
tryptophan, lysine, histidine and glutamic acid. Shown below each metabolite plot are results 
for the same metabolites separated by gender. Blue plots denotes male results only and red 
plots denote females results only for each study. 
2.2. Multivariate Analysis of Data by PLS-LDA  
Multivariate analysis [23] using partial least square (PLS) [24] with linear discriminant analysis 
(LDA) with and without adjusting for age and gender was also performed to determine whether the blood 
metabolome as a combination of all metabolites identified in this study could discriminate cancer cases 
from control samples. PLS was used to reduce the 437 spectral peaks, each representing a metabolite, to 
a smaller number of latent components that distinguished cancer cases and controls and then determined 
which peaks were most influential in separating cases and controls as possible biomarkers. Metabolomic 
results from the cases and controls of Study 1 were separated by the first and second components when 
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adjusted for age and sex (Figure 2A) that also showed good separation when the results were not adjusted 
for co-variants (Figure 2C). Based on leave-one-out cross-validation (LOOCV), we attempted to assess 
the performance of the metabolites to correctly identify the cancer cases. Sixty-three % of Study 1 
samples were correctly classified , with 66.7% sensitivity and 60% specificity when two latent components 
were used to predict cancer status with adjustment for age and gender (Table S3A) and without 
adjustment for age and gender (Table S3B).  
 
Figure 2. Multivariate PLS separates lung cancer patients and controls in two independent 
studies by the global metabolomic profiles. (A) PLS of Study 1 data results with gender and 
age adjusted; (B) PLS of Study 1 without gender and age adjusted; (C) PLS of Study 2 with 
gender and age adjusted; (D) PLS of Study 2 without gender and age adjusted. Red squares 
denote control cases and solid blue circles denote cancer cases. 
For Study 2, PLS-LDA analysis also showed separation for cancer based on metabolic profiles with 
adjustment for gender and age (Figure 2B) as well as for metabolic profiles without adjustment for 
gender and age (Figure 2D). Based on LOOCV, 68% of Study 2 samples were correctly classified with 
sensitivity 63.6%, specificity 72.7% when two latent components were used to predict cancer status with 
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adjustment for age and gender (Table S4A). However, the PLS analysis without age and sex adjustment 
yielded better separation of the groups for Study 2 samples (Figure 2D). Using two latent components 
meant 81.8% were correctly classified with sensitivity 72.7%, specificity 90.9%, suggesting an influence 
of covariants (Table S4B).  
2.3. Detection of Unknown Metabolites  
Some of the metabolites that we found to be differentially expressed were unknown compounds 
(Tables S1 and S2). We have intentionally used an untargeted metabolomic screen to detect novel 
metabolites that might be involved in the pathogenesis of NSLC and thereby detected “unknown” 
compounds in our metabolomic analysis. Most of these unknown compounds have been previously 
observed in other samples from different species, mammalian (human, mouse, rat), plant, bacterial and 
others which have been carefully tabulated in the BinBase database [25]. Searching our BinBase 
database and comparing the MS spectra of the unknowns with known compounds with similar electron 
ionization fragment spectra and similar retention times can help identify several interesting compounds 
that the unknown may be linked or is related to, based on the similarity of the spectra to known spectral 
fragmentation (Figure 3). For example, based on its fragmentation scan, the BinBase unknown 
compound #200595 has evidence of being an amino-compound, #200595 shows substructure patterns 
of carbohydrates and a retention index close to glucoheptose, #220177 can also be matched to 
carbohydrate substructures, in addition to showing a characteristic fragment m/z 144 typical for amines, 
and #223597 is a very high boiling compound with fragments found in sterols. Once additional cohort 
studies validate the importance of such unidentified metabolites, accurate mass GC-QTOF MS data can 
be acquired to obtain elemental formulas and matching structures from database queries [26,27]. 
 
Figure 3. Box plots of top unknown compounds with electron ionization mass spectra 
comparing the two studies. Box-whisker plots (top panels) of the top unknown candidates 
from each study (Study 1 and Study 2) with the electron ionization MS spectra (lower panels) 
of the compound to show the mass fragmentation of the compounds to help with the 
identification of the compound.  
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2.4. Discussion  
2.4.1. Systemic Metabolic Changes in Blood from Lung Cancer Patients 
The most significant metabolite changes were representative of changes in amino acid, energy, fatty 
acid and lipid metabolism. Amino acid differences have been reported in NSCLC and other cancers in 
plasma [10,12,16,17,28] with Maeda et al. reporting that concentrations of Ser, Pro, Gly, Ala, Met, Ile, 
Leu, Tyr, Phe, Orn and Lys were higher and histidine was lower in NSCLC compared with controls [17], 
while Cascino et al. reported increases in Trp, Glu and Orn (Arg) in lung and breast cancers in blood [29]. 
Other amino acid changes we detected were consistent with a recent report by Miyagi et al. [30] who 
identified decreases in histidine, glutamine and threonine in early and late lung cancer in plasma samples 
from five cancers (lung, gastric, colorectal, breast and prostate). Miyagi et al. also reported that histidine 
was decreased in all but prostate cancer. Tryptophan was decreased in all five cancers in Miyagi’s study [30], 
which we also identified as decreasing in our two studies. A general difference between the two studies 
is that Miyagi’s study focused on the analysis of early stage cancers (Stage I–III) whereas Rossi Fanelli’s 
studies analysed cancer anorexia in very late stage cancers [31,32]. 
Other studies in lung cancer in blood plasma have been conducted by NMR. Rocha et al. [33] detected 
metabolic changes related to glycolysis, glutaminolysis and gluconeogenesis with suppressed Krebs 
cycle and reduced lipid catabolism as a metabolic signature for lung cancer in 85 lung cancer patients 
and 78 healthy controls using NMR analysis. The average age for the lung cancer patients was 63 yr 
(30–85 yr) versus non-diseased control with an average age of 41 yr (22–60 yr) showing an age 
difference between the cases and controls. Histopathology of the cases ranged from 43% (37 cases) of 
adenocarcinoma with the rest a combination of epidemoid carcinoma, carcinoid, large cell and small cell 
carcinoma, with mostly early stage (81% Stage I and Stage II), and a few late stage (8% Stage III). Our 
Study 1 focused only on NSCLC adenocarcinoma with better matched controls for age and smoking 
history and all late stage disease. Hence, the metabolomic biomarkers we describe may be more 
associated with late stage, metastatic disease. We understand that the reason  most experimental 
biomarkers fail in clinical validation studies for early detection is that the biomarkers were discovered 
in late stage cancer cases,  and are unsuitable as biomarkers for early stage disease [34,35]. We still need 
to conduct studies on early stage lung cancer (Stage I-II) matched with suitable gender, age and smoking 
history controls to better characterize biomarkers of early lung cancer. Comparing the results from 
plasma and serum blood samples has already been shown to be marked similar for the two biofluids by 
Wedge et al. for small cell lung cancer (SCLC) [36]. Also, our studies complement those of the SIRM 
and NMR tissue and blood studies in lung cancer [17,22,37]. These studies require the infusion of C13 
stable isotopes into the patient before analysis and are not practical for the clinical laboratory. The results 
from two studies add to the growing body of evidence that metabolomic changes detectable in blood and 
tissue could be used to detect and diagnose lung cancer.  
2.4.2. Pathway Analysis and Overall Metabolic Effect on Blood Metabolites  
While diagnosis of lung cancer phenotypes is clinically important, a differential analysis of plasma 
metabolic changes between lung cancer patients and matched controls should also reflect known 
mechanisms in cancer biology or lead to new hypotheses. We have therefore used less stringent thresholds 
Metabolites 2015, 5 201 
 
 
(p < 0.1) to increase the number of metabolites that are potentially metabolically connected and visualized 
all metabolites at p < 0.1 using a combined biochemical and chemical network graph, MetaMapp (Figure 4). 
This graph clusters metabolites based on biochemical reactant pairs in the KEGG RPAIR Database [38,39] 
in addition to Tanimoto chemical structure similarity for identified metabolites that lack enzymatic 
information [40]. This type of analysis gives us a better perspective on how metabolic changes detected 
in blood samples might be due to the overall systemic effect of tumour growth and helps us to identify 
the potential biochemical links between the metabolic changes in blood from lung cancer (Figure 4). 
The use of MetaMAPP graphs enable understanding which metabolic modules are more affected by a 
disease or a treatment than others [40]. For example, few hydroxyl acids were differentially regulated, 
which means that trichloroacetic (TCA) cycle metabolites in blood plasma did not reflect the disease 
status, whereas plasma lactic acid was significantly increased in ACD NSLC patients. A range of both 
proteinogenic (tryptophan, lysine, histidine, valine) and non-proteinogenic amino acids (N-methylalanine, 
trans-4-hydroxyproline, cis-4-hydroxyproline) were found at lower levels in cancer patients, reflecting 
the increased use of carbon skeletons of amino acids in tumor cells. Reduced levels of amino acids have 
also been observed in cancer cachexia showing greater protein turnover and metabolism in advanced 
stage disease [41].  
 
Figure 4. MetaMapp mapping of metabolomic analysis of lung cancer blood samples: a 
MetaMapp clustering metabolites based on biochemical reactant pairs in the KEGG RPAIR 
Database in addition to Tanimoto chemical structure similarity for identified metabolites that 
lack enzymatic information. 
Interestingly, the most prevalent changes were seen in fatty acid/lipid biosynthesis (Figure 4). Several 
fatty acids were found to be up-regulated, including the important building blocks palmitate, stearate 
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and palmitoate, but also precursors for complex lipids such as glycerol and ethanolamine. The general 
increase in lipid biosynthesis is well established in tumor metabolism but has not been linked to plasma 
levels before. Conversely, peroxidative lipid breakdown products such as the dicarboxylic acids adipate 
and azelaic acid appear to be lowered in lung cancer patients, which may be linked to signalling functions 
or may indicate a lowered use of oxidative pathways in lipid metabolism in tumors. All of these 
possibilities are presently speculative and the actual mechanisms would need to be confirmed in more 
extensive studies. 
2.4.3. Metabolomic Biomarker Potential for Lung Cancer Detection-Clinical Use  
PLS and LDA were used on each study to determine if cancer and control samples could be separated 
and predicted based on metabolic profiles with data adjusted for sex and age or not. Using leave-one-out 
cross validation (LOOCV) of the results, which were regressed for sex and age, identified two latent 
components in Study 1 that were found to have sensitivity and specificity of 66.7% and 60% respectively 
and in Study 2 with a sensitivity of 63.6% and specificity of 72.7% (Tables S3A,B and S4A,B). We 
conclude from these results that our studies were not sufficiently robust to enable satisfactory biomarker 
identification. Our results do show similar results between cases and controls from two groups of 
samples. These results provide additional evidence for the use of metabolomic analysis to identify lung 
cancer biomarkers and support what others have already reported. Our results also add to our growing 
knowledge of the systems biology of lung cancer through our pathway analysis. However, considerably 
better performance characteristics than what we obtained here will be needed for clinical use. High 
specificity of biomarkers (>90% and 95%) will be necessary to adequately reduce false positive rates in 
lung cancer. It might be more feasible to use metabolomic biomarkers in the clinic to help monitor 
treatment and for recurrence. Again it will be important to have good sensitivity for this clinical 
application. We would need performance characteristics more similar to what is now being measured 
with current miRNA studies [42]. We are already conducting better designed studies with larger sample 
sizes with the goal of identifying suitable lung cancer biomarkers using metabolomic analysis. It may 
also be necessary to have a combination of different biomarkers or even a metabolomic profile to provide 
sufficient performance characteristics for clinical utility. The next hurdle would then be how best to 
adapt such an analysis to the clinical laboratory. 
3. Experimental Section  
3.1. Patient Samples 
Pre-existing patient blood samples were acquired from the biorepositories of two institutions 
(FHCRC and UCDMC), all collected and stored at −80 °C before use in these metabolomics studies. 
Samples were received with all identifiers removed. Each institution supplied an equal number of cases 
and controls (20 cases and 20 controls from FHCRC and 11 cases and 11 controls from UCDMC). 
Samples acquired from FHCRC were referred to as Study 1 (or FHCRC) and samples acquired from 
UCDMC were referred to as Study 2 (or UCDMC). All samples were collected with informed consent 
and following IRB protocols approved by each Institution’s Institutional Review Board, intended for use 
only for research purposes. Collection and storage of clinical samples were conducted in accordance 
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with the Declaration of Helsinki with protocols approved by each institution (Gandara IRB protocol 
255991-3). Blood samples (plasma) in Study 1 (FHCRC study) were taken from newly diagnosed lung 
cancer patients with NSCLC adenocarcinoma (mostly late stage) and were frequency matched with for 
age, gender and for general smoking history (current and former smokers) (Table 1A). Controls for this 
study were blood samples collected from individuals who were cancer free and with no history of cancer 
and who were current or former smokers. Blood (plasma) was collected using EDTA tubes (fasting 
conditions unknown), processed into plasma using approved protocols and stored at −80 °C. 
The second set of blood samples (Study 2) came from patients diagnosed with lung cancers (different 
types) (11 cases) that were frequency matched (age and gender) with samples from individuals without 
cancer and with no history of cancer (11 controls). These samples were obtained from the UC Davis 
Cancer Center Biorepository (CCB) and the UC Davis Clinical laboratory at the UC Davis Medical 
Center (UCDMC)(Table 1B). Smoking history and treatment status were known for most of the cases 
in Study 2, but not known for some of the control group. Fasting status of patients and controls were 
unknown. All blood samples (plasma and serum) were prepared using standard clinical SOPs specified 
at each institution and stored at -80 °C until use. De-identified samples from each study were blinded 
and then subjected to metabolomic analysis as previously described [43–45] or described in the 
following methods section. 
3.2. Non-Targeted Metabolomics Analysis by ALEX-CIS-GC/TOF MS 
Samples were stored at −80 °C prior to analysis. Samples were thawed and 30 µL of each sample was 
extracted and derivatized, and metabolite levels were quantified by gas chromatography time-of-flight 
(GC-TOF) mass spectrometry as previously described (38). Briefly, a 30 µL sample was extracted with 
1 mL of degassed acetonitrile:isopropanol:water (3:3:2) at 20oC, centrifuged, the supernatant removed 
and solvents evaporated to dryness under reduced pressure. To remove membrane lipids and triglycerides, 
dried samples were reconstituted with acetonitrile/water (1:1), decanted and taken to dryness under 
reduced pressure. Internal standards, C8–C30 fatty acid methyl esters (FAMEs), were added to s 
amples and derivatized with methoxyamine hydrochloride in pyridine and subsequently by MSTFA  
(Sigma-Aldrich) for trimethylsilylation of acidic protons and analysed by GC-TOF mass spectrometry.  
An Agilent 6890 gas chromatograph (Santa Clara, CA) was used with a 30 m, 0.25 mm i.d. Rtx5Sil-MS 
column with 0.25 μm 5% diphenyldimethylsiloxane film.A Gerstel MPS2 automatic liner exchange 
system was used to inject 0.5 µL of sample at 50 °C (ramped to 250 °C) with 25 s splitless injection 
time. An Agilent 6890 gas chromatograph (Santa Clara, CA, USA) was used with a 30 m, 0.25 mm i.d. 
Rtx5Sil-MS column with 0.25 μm 5% diphenyldimethylsiloxane film. An additional 10 m integrated 
guard column was used (Restek, Bellefonte, PA, USA). Chromatography was performed at a constant 
flow of 1 ml/min, ramping the oven temperature from 50 °C to 330 °C with a 22 min total run time. 
Mass spectrometry was conducted by a Leco Pegasus IV time of flight mass spectrometer with a 280 °C 
transfer line temperature, electron ionization at −70 V and an ion source temperature of 250 °C. Mass 
spectra were acquired from m/z 85–500 at 20 spectra s-1 and 1750 V detector voltage. All samples were 
analyzed in one batch, throughout which data quality and instrument performance were monitored using 
quality control and reference plasma samples (National Institute of Standards and Technology, NIST). 
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3.3. Raw Data Processing and Chemometrics 
Acquired spectra were further processed using the BinBase database [25,46]. Raw data files from the 
GC-TOF mass spectrometer were processed using proprietary software provided by the instrument 
company (Leco, ChromaTOF software (v. 2.32)) for peak finding and mass spectral deconvolution. 
Result files were exported and filtered for consistency using the UC Davis Metabolomics BinBase 
database. All metabolite spectra in BinBase [25] were matched against the Fiehnlib mass spectral library 
of 1200 authentic metabolite spectra using retention index and mass spectrum information in addition to 
the NIST05 commercial library. All output files were stored in the miniX study design database system. 
Identified metabolites were named by biochemical names, KEGG, referenced to PubChem as 
authoritative NIH/NCBI database and InChI hash keys encoding the chemical structures (Table S3). 
Further details of the BinBase algorithm and spectral libraries are given in Scholz and Fiehn [46] and 
Kind et al. [25].  
3.4. Differential Analysis and Partial Least Squares Analysis  
Prior to statistical analyses, metabolite intensities were mean normalized and log2 transformed to 
meet underlying assumptions of normality with a constant variance and to reduce the dominant effect of 
extreme values. Differential analyses were conducted of each study (Study 1 and Study 2) to identify 
individual metabolites that differed between cancer and control subjects. For each study, a difference in 
mean intensity of each metabolite between cancer and control subjects was evaluated with an Analysis 
of Covariance (ANCOVA) which included gender and age as covariates. The significance of difference 
in each metabolite’s intensity by cancer statue was determined based on partial-F statistics using a 
parametric null distribution for each study. False discovery rates (FDRs) were calculated to account for 
multiple testing (Table S2).  
Partial least squares (PLS) regression and linear discriminant analysis (LDA) [24,47] were conducted 
on the metabolomic data to determine if cancer and control patients could be separated and thereby 
predict the sample classification based on global metabolomic profiles. PLS regression was performed 
to reduce the intensity measures of the total number of 437 peaks to a smaller number of latent 
components that explained most of the variation in the data. Leave-one-out cross validation (LOOCV) 
was used to determine the optimal number of latent components to use for the LDA for each study. 
Through LOOCV, the class membership of each excluded subject (cancer or control) was predicted with 
LDA using 1 through 10 latent components identified with the other subjects. For each number of latent 
components evaluated, the misclassification rate was calculated. The number of latent components 
yielding the lowest misclassification rate was considered optimal. 
Each study was analysed separately. We conducted the PLS-LDA for each study in two ways. 
Because gender and age could be confounding factors, in the first analysis we adjusted for these factors 
by using the residuals from a linear regression of metabolite intensities versus gender and age in the 
PLS-LDA. In the second analysis, metabolite intensities were not adjusted for age and gender. For all 
analyses, the misclassification rate, sensitivity and specificity of the PLS-LDA for 1 through 10 latent 
components were calculated through leave-one-out cross validation (Tables S3A,B and S4A,B). In 
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addition, R2, Q2, the percent variation in the metabolite intensities explained by the PLS regression were 
calculated. PLS and LDA analyses were conducted with the R package plsgenomics [48]. 
3.5. MetaMapp Mapping of Identified Compounds 
Molfile encoded chemical structures were retrieved from the PubChem database using PubChem 
identifiers of the identified metabolites. The structures were subjected to pairwise Tanimoto chemical 
similarity coefficient calculations using an online structure clustering tool available at PubChem website. 
For this analysis we relaxed the stringency of the statistical analysis of metabolites and included those 
with p < 0.1 to increase the number of metabolites that are potentially metabolically connected. This 
graph clusters metabolites based on biochemical reactant pairs in the KEGG RPAIR Database [38] in 
addition to Tanimoto chemical structure similarity for identified metabolites that lack enzymatic 
information [40]. The resulting similarity matrix was downloaded and used as an input for MetaMapp 
mapping software [40] at www.metamapp.fiehnlab.ucdavis.edu. A network graph of one-reaction steps 
for the metabolites that were annotated with KEGG identifiers was calculated using MetaMapp software. 
Generated network graphs were imported into Cytoscape and were visualized using organic layout 
algorithm. Results of ANOVA statistics were converted into a node-attributed file using an online tool 
available on the MetaMapp website. Directions of differential alterations were visualized as node color 
and fold-changes were visualized as node size. 
4. Conclusions  
We analysed blood samples from lung cancer cases and matched controls to determine whether 
metabolomic analysis of blood by GC-MS has the potential to be used to detect the presence of lung 
cancer. Similar metabolic differences were detected in two pilot studies. Generally, energy or 
carbohydrate metabolites (maltose, glycerol, lactic acid) increased, amino acids (tryptophan, lysine, 
histidine decreased and certain fatty acids (palmitic acid) increased in both studies.  
What is valuable about our studies is the overall finding that metabolomic analysis has the potential 
to distinguish blood samples of patients with lung cancer from those without cancer. This type of analysis 
has potential for clinical use to aid diagnosis, especially if it can help identify different types of lung 
cancer (NSCLC from SCLC or adenocarcinoma from squamous), which could impact the type of 
treatment. Furthermore if metabolomic biomarkers and a systems biology approach can be proven to 
have high specificity, this type of analysis/assay could possibly help reduce the high false positive rate 
for low-dose CT screening. Clinical use would require adaptation to the clinical laboratory, which we 
foresee would not be difficult since there are already mass spectrometers in clinical chemistry being used 
to analyse specific chemicals and drugs. Target assays for specific metabolites could be developed for 
the clinical laboratory and used for blood testing.  
These findings support the idea that metabolic changes measurable in blood samples are indications 
of early systemic metabolic consequences of lung cancer, which could potentially be useful in a clinical 
setting to enhance present diagnostic methods. In addition to aiding diagnosis of lung cancer, 
metabolomic and other types of biomarkers analysis (proteomics, glycomics, miRNA) could accompany 
present imaging methods such as low-dose CT scan screening to reduce its high false positive rate for 
malignant lung cancer if early metabolic changes related to progression of cancer can be detected in 
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blood samples. Further investigations into the use of metabolomic analyses of blood samples in much 
larger clinical studies are needed in order to adequate assess the clinical value of this type of analysis. 
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